Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many claims are not supported by the provided FDA label excerpts (especially non-label topics like generics, pricing, patents, biosimilars). Several acne indication subtypes (acne conglobata/fulminans) cannot be verified from provided labeling sections. High-risk safety-critical label content (boxed warning, contraindications, pregnancy/iPLEDGE) is not cited in the evaluation, preventing adequate verification of dangerous omissions.
Category Scores
Accurate Statements
Claravis is the brand name for isotretinoin.
MEDICATION GUIDE: "Active Ingredient: Isotretinoin; Rx only"
Isotretinoin can cause skin and mucous membrane reactions.
Clinical Trials and Postmarketing Surveillance: dryness of the skin and mucous membranes (e.g., lips, nasal passage, eyes); MEDICATION GUIDE: "skin problems"
Isotretinoin can cause muscle pain.
MEDICATION GUIDE: "bone and muscle problems... pain in your joints or muscles" and "back pain"/"joint pain"
Isotretinoin can cause psychological effects.
Psychiatric Disorders section and MEDICATION GUIDE: depression, psychosis, suicidal thoughts/acts
Unsupported Statements
Isotretinoin is an oral derivative of vitamin A.
The provided excerpts do not contain this statement; no label text provided to support it.
Isotretinoin is used to treat acne conglobata.
INDICATIONS AND USAGE section text is not provided in the excerpts; no support for conglobata in provided labeling.
Isotretinoin is used to treat acne fulminans.
INDICATIONS AND USAGE section text is not provided in the excerpts; no support for fulminans in provided labeling.
Generic versions of isotretinoin are approved for sale in the United States.
No information about generics in the provided label excerpts.
Generic versions of brand-name drugs must meet the same standards of quality and potency as their branded counterparts.
No generics/quality/potency regulatory equivalence statements provided in the label excerpts.
The manufacturer may change during the production and distribution of the generic version.
No information provided in the label excerpts about generic manufacturing/distribution changes.
Generic versions of isotretinoin must have the same active ingredient (isotretinoin) as the brand-name medication.
No generic equivalence statements provided in the label excerpts.
Generic versions of isotretinoin must have the same dose strength as the brand-name medication.
No generic equivalence statements provided in the label excerpts.
Generic versions of isotretinoin must have the same dosage form as the brand-name medication.
No generic equivalence statements provided in the label excerpts.
The main differences between generic and brand-name isotretinoin are typically in the inactive ingredients, packaging, and appearance.
No generic vs brand comparison statements provided in the label excerpts.
These variations usually do not impact the effectiveness of the medication.
No generic effectiveness statements provided in the label excerpts.
Generic medications meet specific quality and efficacy standards before they are approved for sale.
No generics approval/quality/efficacy standards statements provided in the label excerpts.
Some rare cases have highlighted instances where substandard or ineffective active ingredients may have been used in manufactured tablets.
No such statement provided in the label excerpts.
Generic isotretinoin carries the same potential side effects as the brand-name medication.
No label excerpts provided discussing side-effect equivalence between generics and brand-name products.
The cost of a generic medication typically is significantly lower than its brand-name counterpart.
Pricing/cost claims are not included in the provided FDA label excerpts.
Generic versions of isotretinoin are often significantly cheaper than Claravis.
Pricing/cost claims are not included in the provided FDA label excerpts.
Claravis can range from $900 to $1,300 in a 30-day supply.
Pricing/cost claims are not included in the provided FDA label excerpts.
The patent for Claravis, held by Valeant Pharmaceuticals, expired in 2014.
No patent/ownership/timing information provided in the label excerpts.
Biosimilars for isotretinoin are available.
No biosimilars information provided in the label excerpts.
Biosimilars are medications that are highly similar to an existing medication but produced by a different manufacturer.
No biosimilar definition provided in the label excerpts.
Contradictions
Important Omissions
Any citation or discussion of the boxed contraindication/warning and iPLEDGE REMS pregnancy restrictions (e.g., pregnancy/life-threatening birth defects; must not be used in patients who are or may become pregnant; iPLEDGE special restricted distribution program requirements).
Importance:
High
Core dosage/administration instructions (oral administration with a meal; dosing range 0.5–1 mg/kg/day in two divided doses; duration 15–20 weeks; not established/once-daily not recommended; swallow whole; food affects absorption).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and non-label claims predominate; moreover, the evaluation does not verify inclusion/citation of the most safety-critical labeling elements (pregnancy contraindications/boxed warning and iPLEDGE requirements). While some adverse-effect categories are supported, absence of verified pregnancy/iPLEDGE content prevents assessing alignment on major safety obligations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (especially generics/biosimilars/pricing/patents and acne subtypes conglobata/fulminans), and safety-critical iPLEDGE/pregnancy boxed warning content is not verified.
Suggested Improvement
Restrict claims to text directly present in the provided label excerpts; add label-grounded citations for indication subtype and any safety statements, and include the boxed contraindication/pregnancy and iPLEDGE REMS requirements when addressing safety.